Skip to main content
News and Events

CIR New and Noteworthy

Information about CIR research, vaccines in the news, infectious diseases, and articles featuring CIR staff and faculty.

CIR Research and Articles featuring Faculty & Staff

mosquitos in a feeding container

Learning more about mosquito transmission may help flavivirus vaccine development

An inpatient challenge study being conducted by CIR's team FIRE aims to learn more about how zika is transmitted between them and humans.

Photo of dengue rash on study volunteer

Infecting volunteers with dengue virus shows experimental drug’s promise

Study leader Anna Durbin discusses the power and limits of a provocative human challenge trial

mosquito

Scientists deliberately gave women Zika — here’s why

Findings from a challenge study conducted by CIR's Team FIRE indicate that the two strains of Zika administered in the trial can be safely and effectively used to infect participants in a Zika vaccine trial.

scientist photo

How Human Challenge Trials Accelerate Vaccine Development

Vaccinated, intentionally infected, and sequestered in a hospital unit, volunteers help researchers fast-track promising vaccine candidates.

Vaccines in the News

mosquito

FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus

The U.S. Food and Drug Administration approved Ixchiq, the first chikungunya vaccine. Ixchiq is approved for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus.

canva vaccines syringe and virus molecule

COVID-19 vaccination campaign saved 2.4 million lives, according to health economists

A working paper by researchers from the University of Southern California and Brown University analyzed the global impacts of COVID-19 vaccines.

vaccination photo

Getting a Flu Vaccine and a COVID-19 Vaccine at the Same Time

Coadministration of vaccines refers to giving or getting more than one vaccine during a visit. This is common clinical practice. While there are some exceptions, many vaccines can be given at the same visit.

vaccination

First RSV Vaccine Approved in the US

The U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Read Journal Articles from our Faculty